Fifth Third Bancorp’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Fifth Third Bancorp’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-129	Closed	-$277	–	2625
2024 Q3	$277	Hold	129	–	–	﹤0.01%	2521
2024 Q2	$666	Hold	129	–	–	﹤0.01%	2368
2024 Q1	$690	Hold	129	–	–	﹤0.01%	2297
2023 Q4	$1K	Hold	129	–	–	﹤0.01%	2410
2023 Q3	$510	Hold	129	–	–	﹤0.01%	2509
2023 Q2	$406	Hold	129	–	–	﹤0.01%	2566
2023 Q1	$344	Hold	129	–	–	﹤0.01%	2721
2022 Q4	$463	Hold	129	–	–	﹤0.01%	2605
2022 Q3	$1K	Buy	+129	New	+$1.05K	﹤0.01%	2612

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Fifth Third Bancorp's SYRS Position: Q4 2024 in Review

Fifth Third Bancorp sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 129 shares — an estimated $277 sold.

Fifth Third Bancorp first reported a position in SYRS in Q3 2022 and held it in 9 quarters. The position peaked at $1K in Q4 2023. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

Fifth Third Bancorp reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Fifth Third Bancorp sold 129 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $277.
Fifth Third Bancorp first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2022 and held it in 9 quarters.
Fifth Third Bancorp's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1K in Q4 2023.
44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Fifth Third Bancorp's 13F filing for Q4 2024, filed 21 Jan 2025.